Kinetically-based multiple drug treatment for advanced head and neck cancer.
A multiple drug regimen was given to 36 patients with advanced carcinomas of the head and neck. In 19 of the 24 patients who were assessable the tumour regressed more than 50%; in one it regressed by 25%; and in four it did not respond at all. Multiple drug chemotherapy should be given much earlier in the course of these cancers, preferably as an adjuvant to surgery or radiotherapy.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004428:Ear Neoplasms / Q000188:drug therapy; D005472:Fluorouracil / Q000627:therapeutic use; D006257:Head; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D008441:Maxillary Neoplasms / Q000188:drug therapy; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009062:Mouth Neoplasms / Q000188:drug therapy; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D014062:Tongue Neoplasms / Q000188:drug therapy; D014067:Tonsillar Neoplasms / Q000188:drug therapy; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D015122:Mercaptopurine; D005472:Fluorouracil; D006918:Hydroxyurea; D008727:Methotrexate